UroGen Pharma Ltd (URGN) News

Form ARS - Annual Report to Security Holders

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

-- Program to Highlight 12-Month Durability of Response Results from the Phase 3 ENVISION Pivotal Trial -- UroGen Pharma Ltd. (Nasdaq: URGN), a...

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

- Presentation June 11, 2024 at 3:20 PM ET - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and...

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...